Your browser doesn't support javascript.
loading
Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial.
Tabarsi, Payam; Anjidani, Nassim; Shahpari, Ramin; Roshanzamir, Khashayar; Fallah, Newsha; Andre, Greiciely; Petrovsky, Nikolai; Barati, Saghar.
Afiliação
  • Tabarsi P; Clinical Tuberculosis and Epidemiology Research Centre, National Research Institute for Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Anjidani N; Department of Medical, Orchid Pharmed Company, Tehran, Iran.
  • Shahpari R; Department of Medical, Orchid Pharmed Company, Tehran, Iran.
  • Roshanzamir K; CinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences.
  • Fallah N; Department of Medical, Orchid Pharmed Company, Tehran, Iran.
  • Andre G; Vaxine Pty Ltd, Adelaide, South Australia, Australia.
  • Petrovsky N; Vaxine Pty Ltd, Adelaide, South Australia, Australia.
  • Barati S; Department of Medical, Orchid Pharmed Company, Tehran, Iran.
Immunology ; 167(3): 340-353, 2022 11.
Article em En | MEDLINE | ID: mdl-35758850
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glicoproteína da Espícula de Coronavírus / Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glicoproteína da Espícula de Coronavírus / Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article